Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track for the second half of 2024 CHATHAM, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Tonix …